Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 08:00 ET | Source: Geron Corporation

Geron Announces Appointment of New Members to its Board of Directors

FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...
March 25, 2026 08:00 ET | Source: NodThera

NodThera to Participate in April Investor Conferences

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address...
March 24, 2026 07:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic A/S - Indkaldelse til ordinær generalforsamling

KØBENHAVN, Danmark, 24. marts 2026 – I overensstemmelse med vedtægternes §§ 10-14 indkaldes herved til ordinær generalforsamling i Bavarian Nordic A/S: Tirsdag den 21. april 2026 kl. 16.00 hos...
March 24, 2026 07:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on ...
March 24, 2026 02:30 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »

Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026. Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. ...
March 24, 2026 02:30 ET | Source: Sanofi Winthrop Industrie

Press release: Availability of the Q1 2026 aide-mémoire

Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First...
March 24, 2026 02:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
March 24, 2026 02:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse

Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients...
March 24, 2026 02:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results...
March 23, 2026 16:05 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...